Associate Professor, Radiation Therapy
I am an Associate Professor in Radiobiology at the Discipline of Radiation Therapy, Trinity College Dublin, Ireland with qualifications from four European universities (B.Sc in health engineering (France, Germany), M. Sc in radiobiology (UK), PhD in clinical medicine (Ireland)). Since my tenured appointment at Trinity College Dublin in 2010, I have developed an internationally-recognised radiobiology laboratory in Ireland.
A year after completion of my phD, I was the recipient of the highly competitive St Luke's Young Investigator Award of the Royal Irish Academy of Medicine for my work on tumour hypoxia and radiation response of prostate tumours. I was appointed Head of Research of the Discipline of Radiation Therapy in 2011 and in this role drove the creation of the Applied Radiation Therapy Trinity (ARTT) research group. Following award of a prostate cancer project grant of the Irish Cancer Society in 2012, I took leadership of the Radiobiology and Molecular Oncology strand within that group. I have since established a unique Irish radiotherapy research network to support translation of my work into improved practice, and developed strong international links. I have built up a good publication track record and mentored a number of PhD and MD candidates. All are now holding positions at leading national and international hospitals and institutions.
I was the first European member of the Scholar-In-Training Committee of the Radiation Research Society (USA) and since then, I took a treasurer position for the Irish Radiation Research Society and recently became the youngest member of the Radiobiology committee, within the European Society for Radiotherapy and Oncology (ESTRO) society. Since 2014, I hold an editorial role for the Nature Journal Scientific Reports.
A passionate radiobiologist with a multi-disciplinary view of radiation oncology, my ambition is to enable the development of radiobiology into the age of personalised medicine.
Publications and Further Research Outputs
Inder, S., O'Rourke, S., McDermott, N., (...), Lynch, T., Marignol, L. , The Notch-3 receptor: A molecular switch to tumorigenesis?, Cancer treatment reviews, 60, 2017, p69-76
O'Brien, R. and Marignol, L., The Notch-1 receptor in prostate tumorigenesis, Cancer Treatment Reviews, 56, 2017, p36-46
Fitzpatrick C, Lynch O, Marignol L., 68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease., Anticancer research, 37, (6), 2017, p2753-2760
Samsuri, N.A.B. and Leech, M. and Marignol, L., Metformin and improved treatment outcomes in radiation therapy â" A review, Cancer Treatment Reviews, 55, 2017, p150-162
Hutchinson, J., Marignol, L. , Clinical Potential of Statins in Prostate Cancer Radiation Therapy., Anticancer research, 37, (10), 2017, p5363-5372
Marignol, L., Notch signalling: The true driver of small cell lung cancer?, Translational Cancer Research, 6, 2017, pS1191-S1196
Haruna, F., Lipsett, A., Marignol, L. , Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis., Anticancer research, 37, (10), 2017, p5343-5353
Lynam-Lennon N., Bibby B., Mongan A., Marignol L., Paxton C., Geiersbach K., Geiersbach K., Bronner M., Bronner M., O"Sullivan J., Reynolds J., Maher S., Maher S., Low MiR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma, Molecular Medicine, 22, 2016, p388-397
Meunier A., Flores A., McDermott N., Rivera-Figueroa K., Perry A., Lynch T., Redalen K., Marignol L., Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells, Heliyon, 2, (5), 2016
Devine A, Marignol L, Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis., Anticancer research, 36, (1), 2016, p5-12
McDermott N., Meunier A., Mooney B., Nortey G., Hernandez C., Hurley S., Hurley S., Lynam-Lennon N., Barsoom S., Bowman K., Marples B., Jones G., Marignol L., Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells, Scientific Reports, 6, 2016
Lawlor H, Meunier A, McDermott N, Lynch TH, Marignol L, Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36, (8), 2015, p6019-28
Lim D, Quah DS, Leech M, Marignol L, Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer., Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2015
Dullea A, Marignol L, MGMT testing allows for personalised therapy in the temozolomide era., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015
McLaughlin, J., Marignol, L., Radiotherapy scheduling using prime numbers, 13, (3), 2014, p317-321
Azmi A, Dillon RA, Borghesi S, Dunne M, Power RE, Marignol L, O'Neill BD, Active surveillance for low-risk prostate cancer: diversity of practice across Europe., Irish journal of medical science, 2014
Flores AN, McDermott N, Meunier A, Marignol L, NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer., Nature reviews. Urology, 11, (9), 2014, p499-507
Martin, L.M., Marples, B., Lynch, T.H., Hollywood, D., Marignol, L., Erratum to Exposure to low dose ionizing radiation: Molecular and clinical consequences [Cancer Lett. 338 (2) (2013) 209-218], 349, (1), 2014
Marignol, L., Targeting notch in prostate cancer - Combination is the key, 11, (7), 2014
Kelada O, Marignol L, Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35, (6), 2014, p5095-100
Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D, Hypoxia, notch signalling, and prostate cancer., Nature reviews. Urology, 10, (7), 2013, p405-13
Vajda A, Marignol L, Barrett C, Madden SF, Lynch T, Hollywood D, Perry AS, Gene expression in prostate cancer: the importance of the endogenous control. , The Prostate, 2013
McDermott N, Meunier A, Lynch T, Hollywood D, Marignol L, Isogenic radiation resistant cell lines: Development and Validation strategies., International journal of radiation biology, 2013
Perry, A.S. and O'Hurley, G. and Raheem, O.A. and Brennan, K. and Wong, S. and O'Grady, A. and Kennedy, A.M. and Marignol, L. and Murphy, T.M. and Sullivan, L. and Barrett, C. and Loftus, B. and Thornhill, J. and Hewitt, S.M. and Lawler, M. and Kay, E. and Lynch, T. and Hollywood, D., Erratum: Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer (International Journal of Cancer (2013) 132:8 (1771-80) DOI: 10.1002/ijc.27798)), International Journal of Cancer, 132, (11), 2013
Davies, A.M., Vajda, A., Ryan, S.L., Marignol, L., New approaches to cell based assays for high content screening and analysis, 18, (3), 2013, p23-28
Martin LM, Marples B, Davies AM, Atzberger A, Edwards C, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells., Cancer letters, 2013
Schoenherr D, Krueger SA, Martin L, Marignol L, Wilson GD, Marples B, Determining if low dose hyper-radiosensitivity (HRS) can be exploited to provide a therapeutic advantage: A cell line study in four glioblastoma multiforme (GBM) cell lines., International journal of radiation biology, 2013
Martin LM, Marples B, Lynch TH, Hollywood D, Marignol L, Exposure to Low Dose Ionizing Radiation: Molecular and Clinical Consequences., Cancer letters, 2013
Røe K, Bratland A, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH, Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer., PloS one, 8, (5), 2013, pe63723
Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D, Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer., International journal of cancer. Journal international du cancer, 2012
James C. Forde, Laure Marignol, Ophelia Blake, Ted McDermott, Ronald Grainger, Vivien E. Crowley, Thomas H. Lynch, Standardization of assay methods reduces variability of total PSA measurements: an Irish study, British Journal of Urology International, 2012
Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG, MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma., Journal of molecular medicine (Berlin, Germany), 2012
O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D, MicroRNAs as putative mediators of treatment response in prostate cancer., Nature reviews. Urology, 2012
Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR, Vascular responses to radiotherapy and androgendeprivation therapy in experimental prostate cancer., Radiation oncology (London, England), 7, (1), 2012, p75
Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D, Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients., Cancer treatment reviews, 37, (8), 2011, p643-54
Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D., Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies, Prostate, 71, (5), 2011
Forde JC, Maginn EN, McNamara G, Martin LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M, Lynch TH, Hollywood D, Marignol L, Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro., Cancer biology & therapy, 11, (4), 2011, p421-8
Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L, Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells., Urologic oncology, 1, 2011
Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L, Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells., Urologic oncology, 1, 2010
Martin LM, Marples B, Coffey M, Lawler M, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data., Cancer treatment reviews, 36, (7), 2010, p518-27
Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG, Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma., Radiation research, 174, (6), 2010, p703 - 711
Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D, Comment on "Androgen-hypersensitive preclinical model of prostate cancer" by Kawata et al., The Prostate, 71, (6), 2010, p559 - 560
Martin L, Coffey M, Lawler M, Hollywood D, Marignol L, DNA mismatch repair and the transition to hormone independence in breast and prostate cancer., Cancer letters, 291, (2), 2010, p142-9
Lynn Martin, Brian Marples, Mary Coffey, Mark Lawler, Donal Hollywood, Laure Marignol, Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity., Radiation Research, 172, (4), 2009, p405 - 413
Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M, The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers., Cancer biology & therapy, 8, (2), 2009, p118-24
Marignol, L., Foley, R., Southgate, T.D., Coffey, M., Hollywood, D., Lawler, M., Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro., The Journal of Gene Medicine , 11, (2), 2009, p169-179
Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG., The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?, Journal of Gene Medicine, 10, (9), 2008, p1032-1038
Marignol L, Coffey M, Lawler M, Hollywood D., Hypoxia in prostate cancer: a powerful shield against tumour destruction?, Cancer Treatment Review, 34, (4), 2008, p313-327
Marignol L, Coffey M, Hollywood D, Lawler M., Radiation to Control Transgene Expression in Tumors., Cancer Biological Therapy, 6, (7), 2007, p1005 - 1012
Marignol L, Lawler M, Coffey M, Hollywood D., Achieving Hypoxia-Inducible Gene Expression in Tumors., Cancer Biological Therapy, 4, (4), 2005, p359-364.
DescriptionMolecular Mechanisms of radiation resistance in prostate tumours Development of biomarkers of biochemical treatment failure following radiation therapy Relevance of tumour hypoxia to disease progression and radiation treatment planning MRI imaging of the prostate
- Development of a Companion diAgnostic teSt for radiotheraPy prostAte canceR patients (CASPAR)
- here is an unmet need to develop companion diagnostic tests that can guide patients and their clinicians through the treatment decision process. This project propose assesses a novel protein for its prognostic and therapeutic potential in high risk radiotherapy prostate cancer patients. The long-term focus of CASPAR is to develop a novel companion diagnostic test and therapeutic combination that can allow personalized prescription of radiotherapy for these patients.
- Funding Agency
- Science Foundation Ireland
- Date From
- Date To
- Prognosis potential of miRNAs in high risk radiotherapy prostate cancer patients
- Failure to identify tumours with a radioresistant phenotype in the 1,000+ Irish prostate cancer patients/year receiving radiation therapy (RT) is associated with recurrence and decreased overall survival in approximatively 300-400 of these men, particularly those with localised Gleason 8-10 prostate carcinoma. This study aims to identify a miRNA panel that can be detected in diagnostic tissue biopsy specimen from high-risk patients, which will assist the identification of the 30-50% who are at greater risk of biochemical failure following RT.
- Funding Agency
- Irish Cancer Society
- Date From
- 01 December 2012
- Date To
- 01 December 2016
- Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?
- Oxygen is essential for optimal cytotoxicity of radiation therapy. In the absence of oxygen at the time of radiation exposure, cell survival is commonly expected to increase by up to three-fold. We proposed that the proportion of cells completely deprived of oxygen within tumours may not be sufficiently large to be clinically significant and hypothesised that the surrounding hypoxic cells in fact may govern tumour response to radiotherapy. To test this hypothesis, this study proposed to re-examine the radioresponse of hypoxic prostate cancer cells and determine the consequences of these potentially clinically relevant oxygen levels.
Invited Presentation, MAASTRO Clinic, The Nederlands. "Developing therapeutic packages for prostate cancer radiotherapy"
Oral Presentation: "Developing therapeutic packages for prostate cancer radiotherapy" Biomarkers in radiation oncology Workshop, OncoRay, Dresden, Germany
Poster presentation - ESTRO Annual Meeting, Turin "Therapeutic potential of the YB-1/Notch-3 interaction in prostate cancer"
Poster presentation "Identification of a miRNAs signature of radioresistance in a prostate cancer model"
Poster presentation -ESTRO Annual Meeting, Barcelona, 2015 "Identification of MiRNAs associated with radioresistance in a prostate cancer model"
Invited Talk "5-step guide to the management of a research project" ESTRO Annual Meeting, Barcelona, September 12-16th 2010
Invited Talk " The treatment Field from the Radiobiologist and Molecular Oncologist's Eye" ESTRO Treatment Planning Course
Poster Presentation "Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?" Radiation Research Society Annual meeting, USA, September 2010( Winner Scholar-in-Training Travel award).
Poster Presentation "Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?" Irish Association for Radiation Research, March 2010
Poster Presentation "Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?" ESTRO Annual Meeting, Barcelona, September 12-16th 2010
Oral Presentation "Hypoxia may participates in disease progression and radioresistance through the induction of Notch-3 and upregulation of DNA repair genes in prostate cancer" Faculty of Radiologist Annual Meeting, Dublin, September 2009
Poster Presentation "Hypoxia may participates in disease progression and radioresistance through the induction of Notch-3 and upregulation of DNA repair genes in prostate cancer" 11th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, Ermatingen, Switzerland, June 2009
Oral Presentation "Hypoxia in prostate tumours: detection, consequences and clinical exploitation" St Lukes Young Investigator Award, Royal Academy of Medicine in Ireland, Dublin, Ireland, January 2009 (Winner St Luke's Young Investigator medal)
Oral Presentation "Hypoxia may participates in disease progression and radioresistance through the induction of Notch-3 and upregulation of DNA repair genes in prostate cancer" Association for Radiation Research, Annual Meeting, Glasgow, UK, June 2009
Invited talk ""Radiation Activated Gene Therapy -A review" Royal College of Surgeons in Ireland, I Faculty Annual Scientific meeting, Dublin, September 2007
Awards and Honours
Irish Cancer Society, Prostate Cancer Project Grant
6th St Lukes Young Investigator Award
Travel Award, Radiation Research Society, USA
Early investigator award, Association for Radiation Research
Student travel award, International Conference for Radiation Research
Institute for Molecular Medicine Best PhD poster competition award
Nominee for the St Lukes Young Investigator Award
Scholar In Training Committee member of the Radiation Research Society (USA)
Scholar In Training Committee member of the Association for Radiation Research (UK)
Scholar In Training Committee member European Society for Therapeutic Radiology and Oncology (ESTRO)
Treasurer, Irish Association for Radiation Research
Irish Association for Cancer Research
Secretary, Irish Association for Radiation Research
Member, Radiobiology Committee, European Society for Radiotherapy and Oncology (ESTRO)